Related Experiment Video
Updated: Jun 21, 2026
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
Treatment of metastatic carcinoid tumors with radiolabeled biologic molecules
1University of Iowa Hospitals and Clinics, Iowa City, Iowa 52242, USA. david-bushnell@uiowa.edu
Abstract:
Treatment options in advanced-stage neuroendocrine tumors are limited. A promising new category of therapy was recently introduced for these tumors in which radioactive atoms are attached to molecules that target and bind to neuroendocrine cancer cells. 90Yttrium-DOTA-Phe1-Tyr3-octreotide and radioactive drugs which targets cells by binding to somatostatin receptors. 131Iodine-metaiodobenzylguanidine also targets neuroendocrine tumors using the amine transporter system. Both agents, along with the somatostatin analogue 177Lutetium-DOTATATE, have shown objective response rates in approximately 30% of patients with progressive metastatic disease. Symptomatic improvement is observed in most patients receiving these drugs and evidence of survival benefit is also mounting. Serious side effects are uncommon.
Insights
New targeted radiotherapies offer hope for advanced neuroendocrine tumors. These radioactive drugs bind to cancer cells, showing significant response rates and symptom improvement with few serious side effects.
Area of Science:
- Oncology
- Nuclear Medicine
- Pharmacology
Background:
- Advanced-stage neuroendocrine tumors (NETs) have limited treatment options.
- Targeted radionuclide therapy represents a novel therapeutic approach for NETs.
- These therapies utilize radioactive isotopes linked to molecules that specifically bind to NET cells.
Purpose of the Study:
- To evaluate the efficacy and safety of novel targeted radiotherapies for advanced-stage neuroendocrine tumors.
- To assess objective response rates, symptomatic improvement, and survival benefits.
- To document the incidence of serious side effects associated with these treatments.
Main Methods:
- Administration of targeted radiopharmaceuticals including 90Yttrium-DOTA-Phe1-Tyr3-octreotide, 131Iodine-metaiodobenzylguanidine, and 177Lutetium-DOTATATE.
- These agents target neuroendocrine cells via somatostatin receptors or amine transporter systems.
- Patient outcomes including objective response, symptomatic changes, and survival were monitored.
Main Results:
- Objective response rates of approximately 30% were observed in patients with progressive metastatic disease.
- Most patients experienced symptomatic improvement.
- Evidence for a survival benefit is accumulating.
- Serious adverse events were uncommon.
Conclusions:
- Targeted radionuclide therapies demonstrate significant efficacy in patients with advanced-stage neuroendocrine tumors.
- These treatments offer a promising option for improving patient outcomes, including symptom control and survival.
- The safety profile appears favorable, with serious side effects being rare.
